Kathleen Earley Email & Phone Number

✦ Specialty Pharmaceutical Sales Representative ✦ Disease State Expertise in ✔︎ Hemophilia ✔︎ Primary Immune Deficiency ✔︎ Hereditary Angio Edema (HAE) ✔︎ Pulmonary Disease/Alpha 1 Throughout my pharmaceutical sales career, I have been on go-to-market teams for numerous products and exceeded sales goals for orphan drugs and chronic disease therapies. My success is fueled by my passion and commitment to patient outcomes and my ability to connect, engage, and sustain meaningful rapport with physicians and patient advocates. AWARD-WINNING SALES PERFORMANCE ⇨ Recognized throughout my career with for exceeding quota, achieving product launch targets, and driving YoY share growth. Most recently, recognized as 2016 Territory Manager of the Year, East Region.PATIENT ADVOCACY⇨ Built and sustained influential relationships with patient advocacy groups in the NY/NJ metro, particularly in the Hemophilia community. PRODUCT LAUNCH⇨ Achieved launch milestones indicated for chronic and orphan disease therapies including iXinity (Hemophilia B); Privagen, Hizentra®, and Vivoglobin® (primary immune deficiency); Berinert® (Hereditary Angio Edema/HAE); and Zemeira® (Alpha 1).SALES STRATEGY⇨ Devised and optimized call planning and targeting tactics to adapt, respond, and overcome challenges related to formulary access, time to market, and other competitive threats.In my current role as Hemophilia territory manager for Aptevo, I have built strategic alliances with Hemophilia patient advocacy groups/physicians and positioned our new-to-market indication, Ixinity®, to achieve launch-year milestones.Prior to Aptevo, I was an Area Sales Manager at CSL Behring, where I delivered 25%+ share increases for drugs in my portfolio and was a key player driving launch of 5 different products.Product Launch – Market Access – Managed Care – Patient Advocacy – Pharmaceutical Sales – KOL Identification – Territory Development – Strategic Sales Planning – Sales Presentations

Listed skills include Pharmaceutical Industry, Pharmaceutical Sales, Patient Advocacy, Orphan Drugs, and 26 others.

• 

  Fairfield University

  Economics